Comparative Pharmacology
Head-to-head clinical analysis: DIULO versus ORETIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIULO versus ORETIC.
DIULO vs ORETIC
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Inhibits the Na+/Cl- symporter in the distal convoluted tubule of the nephron, reducing reabsorption of sodium and chloride, leading to increased diuresis and decreased extracellular fluid volume.
Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, reducing reabsorption of sodium and chloride, leading to increased excretion of water and electrolytes.
HypertensionEdema due to congestive heart failure, hepatic cirrhosis, or renal disease
HypertensionEdema associated with congestive heart failure, cirrhosis, corticosteroid therapy, and nephrotic syndrome
2.5 mg orally once daily, may increase to 5 mg once daily after 4 weeks if needed.
25-100 mg orally once or twice daily; maximum 200 mg/day.
None Documented
None Documented
Terminal elimination half-life is 1.5-2 hours (mean 1.8 h) in healthy adults; prolonged to 3-6 hours in renal impairment and up to 8 hours in severe heart failure.
Terminal elimination half-life: 6-15 hours (average 10 hours); prolonged in renal impairment and heart failure; clinical context: duration of diuretic effect correlates with half-life, requiring once or twice daily dosing.
Primarily hepatic via CYP450 enzymes; minimal first-pass metabolism.
Hydrochlorothiazide is not extensively metabolized; the majority is excreted unchanged in urine.
Primarily renal excretion (60-70% as unchanged drug) via glomerular filtration and tubular secretion; approximately 10-15% biliary/fecal elimination.
Renal: approximately 95% (primarily as unchanged drug via tubular secretion), Biliary/fecal: <5%
95-99% bound to albumin and alpha-1-acid glycoprotein specific; binding is saturable at high concentrations.
Approximately 95% bound to plasma proteins, primarily albumin.
0.13-0.25 L/kg (average 0.2 L/kg) indicating distribution largely within extracellular fluid; Vd increases in edema states.
Vd: 0.2-0.4 L/kg; indicates distribution primarily in extracellular fluid and limited tissue penetration.
Oral bioavailability is 60-70% due to first-pass metabolism; approximately 50% in patients with severe heart failure or edema.
Oral bioavailability: approximately 65-70% (range 50-80%) with significant interindividual variability due to first-pass metabolism and food effects.
eGFR 30-59 mL/min: no adjustment; eGFR 15-29 mL/min: 2.5 mg once daily; eGFR <15 mL/min or on dialysis: not recommended.
GFR 10-50 mL/min: 50 mg orally every 12 hours; GFR <10 mL/min: avoid or use 50 mg orally every 24 hours.
Child-Pugh A: no adjustment; Child-Pugh B or C: not recommended due to lack of data.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use.
Not approved for pediatric patients.
1-2 mg/kg orally once daily; maximum 50 mg/day for children <12 years.
Start at 2.5 mg once daily; monitor renal function and electrolytes closely.
Start at 12.5-25 mg orally once daily; adjust slowly to avoid hypotension and electrolyte imbalance.
None
None
["Hypokalemia","Hyperuricemia","Hypomagnesemia","Hyperglycemia","Hypercalcemia","Sulfonamide allergy cross-reactivity","Excessive diuresis leading to volume depletion and electrolyte imbalance"]
["Hypokalemia: Monitor potassium levels and supplement if necessary.","Hypomagnesemia: May occur, especially with prolonged use.","Hyperuricemia: May precipitate gout attacks.","Sulfonamide allergy: Cross-sensitivity may occur in patients with sulfonamide allergy.","Systemic lupus erythematosus: May exacerbate or activate SLE.","Impaired renal function: Use with caution; may accumulate in severe renal impairment."]
["Anuria","Renal failure","Hepatic coma or pre-coma","Hypersensitivity to sulfonamide-derived drugs","Severe electrolyte abnormalities"]
["Anuria","Hypersensitivity to hydrochlorothiazide or other sulfonamide-derived drugs"]
Data Pending Review
Data Pending Review
Avoid excessive intake of high-potassium foods (e.g., bananas, oranges, potatoes) unless directed. Avoid salt substitutes containing potassium. Grapefruit juice may increase metolazone levels; limit consumption. Avoid alcohol as it may potentiate orthostatic hypotension.
Avoid excessive sodium intake; use salt substitutes cautiously due to potassium content. Grapefruit juice may increase hydrochlorothiazide levels. Alcohol can potentiate hypotension. Avoid large amounts of potassium-rich foods if on potassium supplements or ACE inhibitors.
No adequate studies in pregnant women. Based on animal data, may cause fetal harm. First trimester: possible teratogenic effects (limb defects, CNS malformations). Second/third trimester: risk of fetal hypotension, oligohydramnios, renal impairment, skull ossification defects. Avoid use unless benefit outweighs risk.
FDA Pregnancy Category C. First trimester: No adequate studies; potential risk based on animal data. Second/third trimesters: Possible fetal/neonatal adverse effects including jaundice, thrombocytopenia, electrolyte disturbances. Avoid for pregnancy-induced hypertension or preeclampsia as it may decrease placental perfusion.
Unknown if excreted in human milk. No M/P ratio available. Considered compatible with breastfeeding by most authorities due to low oral bioavailability in infants, but monitor for hypotension, electrolyte disturbances, and decreased milk production.
Excreted in human milk in low amounts. M/P ratio unknown. Use caution; monitor infant for diuretic effects, electrolyte imbalance. May suppress lactation if used in high doses.
Pregnancy increases plasma volume and renal clearance, potentially reducing diuretic efficacy. Consider dose adjustment based on clinical response and edema severity. Avoid excessive dosing to prevent maternal hypovolemia and fetal hypoperfusion. Use lowest effective dose.
Hydrochlorothiazide: No specific dose adjustment guidelines. Increased renal clearance during pregnancy may require dose titration. Avoid for gestational hypertension; limited use for chronic hypertension if benefits outweigh risks. Maximum effect with 25-50 mg daily; doses >50 mg may increase placental hypoperfusion risk.
Category C
Category C
Diulo (metolazone) is a thiazide-like diuretic used for hypertension and edema. Its long half-life allows once-daily dosing. Monitor for hypokalemia, hyponatremia, and hyperuricemia. Synergistic effect when used with loop diuretics for refractory edema. Avoid in severe renal impairment (CrCl <20 mL/min).
ORETIC (hydrochlorothiazide) is a thiazide diuretic. Monitor serum potassium and glucose, especially in diabetic patients. Use cautiously in patients with renal impairment (CrCl <30 mL/min is relative contraindication). Can exacerbate gout by increasing serum uric acid. Onset of diuresis is 2 hours, peak at 4-6 hours, duration 6-12 hours.
Take exactly as prescribed, usually once daily.May cause increased urination; take in morning to avoid nighttime disruption.Avoid alcohol and NSAIDs unless approved by your doctor.Report signs of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat.Monitor blood pressure regularly.Avoid prolonged sun exposure; use sunscreen due to photosensitivity risk.Do not stop abruptly without consulting your doctor.
Take in the morning to avoid nocturia.May cause dizziness due to dehydration; rise slowly from sitting or lying down.Avoid prolonged sun exposure; use sunscreen as this drug can increase photosensitivity.Report symptoms of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, excessive thirst.Do not consume grapefruit juice as it may increase drug levels and risk of side effects.